Durham, North Carolina
United States
136
2026-05-14
51
2026-06-02
These are the the leading inventors for applications assigned to PRECISION BIOSCIENCES, INC.:
PRECISION BIOSCIENCES, INC. based in Durham, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#2 | 2026-04-30OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#3 | 2026-03-19MUSCLE-SPECIFIC EXPRESSION CASSETTES
#4 | 2026-01-29ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME
#5 | 2026-01-29ANTIBODIES AND FRAGMENTS SPECIFIC FOR B-CELL MATURATION ANTIGEN AND USES THEREOF
#6 | 2025-12-18 ✅ Patent 12,644,135 granted on 2026-06-02POLYPEPTIDE LINKERS FOR USE IN ENGINEERED MEGANUCLEASES
#7 | 2025-11-13ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME
#8 | 2025-10-30OPTIMIZED ENGINEERED NUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#9 | 2025-10-09GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED TRANSFERRIN GENE
#10 | 2025-10-02GENETIC MODIFICATION OF THE HYDROXYACID OXIDASE 1 GENE FOR TREATMENT OF PRIMARY HYPEROXALURIA
#11 | 2025-05-29OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME
#12 | 2025-05-15ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE HEPATITIS B VIRUS GENOME
#13 | 2025-05-15RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
#14 | 2025-05-15ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE PCSK9 GENE
#15 | 2025-05-15GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR)
#16 | 2025-05-15DYSTROPHIN GENE EXON DELETION USING ENGINEERED NUCLEASES
#17 | 2025-04-24MODULATION OF TGF BETA SIGNALING IN GENETICALLY-MODIFIED EUKARYOTIC CELLS
#18 | 2025-04-17TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES
#19 | 2025-03-13PRECISE DELETION OF CHROMOSOMAL SEQUENCES IN VIVO AND TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS USING ENGINEERED NUCLEASES
#20 | 2025-02-27OPTIMIZED POLYNUCLEOTIDES FOR PROTEIN EXPRESSION
#21 | 2025-02-06METHODS FOR CANCER IMMUNOTHERAPY
#22 | 2025-01-30POLYNUCLEOTIDES ENCODING ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR RECOGNITION SEQUENCES IN THE DYSTROPHIN GENE
#23 | 2025-01-23 ✅ Patent 12,595,470 granted on 2026-04-07ENGINEERED NUCLEASES THAT TARGET HUMAN AND CANINE FACTOR VIII GENES AS A TREATMENT FOR HEMOPHILIA A
#24 | 2025-01-09METHODS FOR CANCER IMMUNOTHERAPY
#25 | 2024-12-05RECOGNITION SEQUENCES FOR I-CREI-DERIVED MEGANUCLEASES AND USES THEREOF
#26 | 2024-11-21NUCLEIC ACIDS ENCODING ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#27 | 2024-09-12ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HYDROXYACID OXIDASE 1 GENE
#28 | 2024-08-15ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE HEPATITIS B VIRUS GENOME
#29 | 2024-07-18TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES
#30 | 2024-06-20ENGINEERED MEGANUCLEASES THAT TARGET HUMAN MITOCHONDRIAL GENOMES
#31 | 2024-05-16DYSTROPHIN GENE EXON DELETION USING ENGINEERED NUCLEASES
#32 | 2024-03-28ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE PCSK9 GENE
#33 | 2024-03-28ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE PCSK9 GENE
#34 | 2024-03-14ENGINEERED MEGANUCLEASES THAT TARGET HUMAN MITOCHONDRIAL GENOMES
#35 | 2024-03-14GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR)
#36 | 2024-02-15ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN BETA-2 MICROGLOBULIN GENE
#37 | 2024-02-01OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME
#38 | 2024-01-18 ✅ Patent 12,006,522 granted on 2024-06-11Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene
#39 | 2024-01-18CO-STIMULATORY DOMAINS FOR USE IN GENETICALLY-MODIFIED CELLS
#40 | 2024-01-11ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE TRANSTHYRETIN GENE
#41 | 2024-01-04 ✅ Patent 11,993,793 granted on 2024-05-28Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene
#42 | 2024-01-04GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#43 | 2024-01-04OPTIMIZED ENGINEERED NUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#44 | 2023-12-28 ✅ Patent 12,351,839 granted on 2025-07-08RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
#45 | 2023-11-16LIPID NANOPARTICLE COMPOSITIONS
#46 | 2023-10-26OPTIMIZATION OF ENGINEERED MEGANUCLEASES FOR RECOGNITION SEQUENCES
#47 | 2023-09-21 ✅ Patent 11,866,747 granted on 2024-01-09Engineered meganucleases that target human mitochondrial genomes
#48 | 2023-09-07 ✅ Patent 11,851,680 granted on 2023-12-26Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
#49 | 2023-06-29PRECISE DELETION OF CHROMOSOMAL SEQUENCES IN VIVO AND TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS USING ENGINEERED NUCLEASES
#50 | 2023-06-22 ✅ Patent 12,595,469 granted on 2026-04-07TREATMENT OF RETINITIS PIGMENTOSA USING IMPROVED ENGINEERED MEGANUCLEASES
#51 | 2023-06-22METHODS FOR IMMUNOTHERAPY
#52 | 2023-06-22METHODS FOR IMMUNOTHERAPY
#53 | 2023-06-15SELF-LIMITING VIRAL VECTORS ENCODING NUCLEASES
#54 | 2023-06-08MODIFIED EPIDERMAL GROWTH FACTOR RECEPTOR PEPTIDES FOR USE IN GENETICALLY-MODIFIED CELLS
#55 | 2023-06-08COMPOSITIONS AND METHODS FOR SEQUENTIAL STACKING OF NUCLEIC ACID SEQUENCES INTO A GENOMIC LOCUS
#56 | 2023-03-23RECOGNITION SEQUENCES FOR I-CREI-DERIVED MEGANUCLEASES AND USES THEREOF
#57 | 2023-02-16 ✅ Patent 11,753,630 granted on 2023-09-12Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene
#58 | 2023-02-02METHODS FOR CANCER IMMUNOTHERAPY
#59 | 2023-02-02 ✅ Patent 12,410,418 granted on 2025-09-09OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME
#60 | 2022-12-29CD20 CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE FOR IMMUNOTHERAPY
#61 | 2022-10-20METHODS AND PRODUCTS FOR PRODUCING ENGINEERED MAMMALIAN CELL LINES WITH AMPLIFIED TRANSGENES
#62 | 2022-09-01LYMPHODEPLETION DOSING REGIMENS FOR CELLULAR IMMUNOTHERAPIES
#63 | 2022-09-01COMPOSITIONS AND METHODS FOR SEQUENTIAL STACKING OF NUCLEIC ACID SEQUENCES INTO A GENOMIC LOCUS
#64 | 2022-08-04ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE HEPATITIS B VIRUS GENOME
#65 | 2022-07-21NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOF
#66 | 2022-06-30METHODS OF PREPARING POPULATIONS OF GENETICALLY-MODIFIED IMMUNE CELLS
#67 | 2022-06-30 ✅ Patent 11,453,861 granted on 2022-09-27Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
#68 | 2022-06-23OPTIMIZATION OF ENGINEERED MEGANUCLEASES FOR RECOGNITION SEQUENCES
#69 | 2022-06-23ENGINEERED NUCLEASES USEFUL FOR TREATMENT OF HEMOPHILIA A
#70 | 2022-05-19NUCLEIC ACIDS ENCODING ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#71 | 2022-05-12GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#72 | 2022-05-12TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES
#73 | 2022-05-05GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#74 | 2022-04-21GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED TRANSFERRIN GENE
#75 | 2022-03-24GENETIC MODIFICATION OF THE HYDROXYACID OXIDASE 1 GENE FOR TREATMENT OF PRIMARY HYPEROXALURIA
#76 | 2022-02-24 ✅ Patent 11,788,077 granted on 2023-10-17Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
#77 | 2022-02-10 ✅ Patent 11,384,335 granted on 2022-07-12Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
#78 | 2021-09-09 ✅ Patent 12,448,613 granted on 2025-10-21GENETICALLY-MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE T CELL RECEPTOR ALPHA GENE
#79 | 2021-08-19 ✅ Patent 11,186,822 granted on 2021-11-30Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
#80 | 2021-07-29PRECISE DELETION OF CHROMOSOMAL SEQUENCES IN VIVO AND TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS USING ENGINEERED NUCLEASES
#81 | 2021-07-08 ✅ Patent 11,268,065 granted on 2022-03-08Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
#82 | 2021-06-17 ✅ Patent 11,274,285 granted on 2022-03-15Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome
#83 | 2021-05-20DYSTROPHIN GENE EXON DELETION USING ENGINEERED NUCLEASES
#84 | 2021-05-06RECOGNITION SEQUENCES FOR I-CREI-DERIVED MEGANUCLEASES AND USES THEREOF
#85 | 2021-04-22 ✅ Patent 11,786,554 granted on 2023-10-17Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
#86 | 2021-02-25RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
#87 | 2021-02-25 ✅ Patent 11,266,693 granted on 2022-03-08Nucleic acids encoding engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene
#88 | 2021-02-04ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN BETA-2 MICROGLOBULIN GENE
#89 | 2021-01-07TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES
#90 | 2020-12-24CO-STIMULATORY DOMAINS FOR USE IN GENETICALLY-MODIFIED CELLS
#91 | 2020-11-26 ✅ Patent 11,008,548 granted on 2021-05-18Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
#92 | 2020-10-29NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOF
#93 | 2020-10-01SELF-LIMITING VIRAL VECTORS ENCODING NUCLEASES
#94 | 2020-09-24ENGINEERED NUCLEASES THAT TARGET HUMAN AND CANINE FACTOR VIII GENES AS A TREATMENT FOR HEMOPHILIA A
#95 | 2020-07-30 ✅ Patent 10,851,358 granted on 2020-12-01Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
#96 | 2020-07-30MODIFIED EPIDERMAL GROWTH FACTOR RECEPTOR PEPTIDES FOR USE IN GENETICALLY-MODIFIED CELLS
#97 | 2020-06-18METHODS FOR REDUCING DNA-INDUCED CYTOTOXICITY AND ENHANCING GENE EDITING IN PRIMARY CELLS
#98 | 2020-06-11 ✅ Patent 10,758,595 granted on 2020-09-01Treatment of retinitis pigmentosa using engineered meganucleases
#99 | 2020-04-30 ✅ Patent 11,680,254 granted on 2023-06-20Engineered meganucleases specific for recognition sequences in the PCSK9 gene
#100 | 2020-04-23 ✅ Patent 11,053,484 granted on 2021-07-06Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene
Also check out Precision BioSciences, Inc.'s (Durham, United States) applicant profile with 82 patent applications submitted.
36992 ⎘